Independent Identification of Handling Errors for Dry Powder Inhalers, Spiromax® and Turbuhaler®, Using a Delphi Process Involving Respiratory Device Experts
Tóm tắt
Correct use of inhalation devices is critical for optimal drug delivery to the lower lung. This Delphi process was conducted to compile lists of potential handling errors when using a Spiromax® or Turbuhaler® inhalation device, as determined by an independent panel. A Delphi process was used to obtain consensus on potential handling errors for each device from ten independent respiratory device experts. In Round 1, advisors listed potential errors with the devices. In Round 2, a severity rating was assigned to each error based on erroneous device handling negatively affecting functionality and treatment effectiveness (error [score 0–3]; potentially critical [4–7]; critical [8–10]). In Round 3, advisors revised their ratings based on the group scores and voted on whether to accept the median severity score as the consensus in Round 4. A total of 29 potential errors for Spiromax and 31 for Turbuhaler were identified in Round 1. After Round 4, consensus was reached for 69% of the Spiromax errors and 94% of the Turbuhaler errors. After completion of the Delphi process, some anomalies were identified in the list of handling errors, which were then investigated with the panel via teleconferences. After teleconferences to discuss discrepancies in the results, there were 22 errors for Spiromax (four critical, 12 potentially critical, and six errors) and 27 for Turbuhaler (nine critical, 14 potentially critical, and four errors). Not inhaling through the mouthpiece, exhaling into the device, and incorrect mouth positioning were identified as critical errors for both devices. Through the Delphi process, advisors independently identified and reached consensus on handling errors for Spiromax and Turbuhaler. Fewer Spiromax errors were classified as critical or potentially critical than with Turbuhaler, indicating that there may be less potential for handling errors with Spiromax. Teva Branded Pharmaceutical Products R & D, Inc.
Tài liệu tham khảo
Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912–9.
Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006;368(9537):744–53.
Haughney J, Price D, Barnes N, Virchow J, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010;104(9):1237–45.
Molimard M, Le Gros V. Impact of patient-related factors on asthma control. J Asthma. 2008;45(2):109–13.
Papi A, Haughney J, Virchow JC, Roche N, Palkonen S, Price D. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J. 2011;37(5):982–5.
Al-Jahdali H, Ahmed A, Al-Harbi A, et al. Improper inhaler technique is associated with poor asthma control and frequent emergency department visits. Allergy Asthma Clin Immunol. 2013;9(1):8.
Arora P, Kumar L, Vohra V, et al. Evaluating the technique of using inhalation device in COPD and bronchial asthma patients. Respir Med. 2014;108(7):992–8.
Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–8.
Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16(3):249–54.
Thomas M. Why aren’t we doing better in asthma: time for personalised medicine? NPJ Prim Care Respir Med. 2015;25:15004.
Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir Med. 2006;100(9):1479–94.
Molimard M. How to achieve good compliance and adherence with inhalation therapy. Curr Med Res Opin. 2005;21(Suppl. 4):S33–7.
Inhaler Error Steering Committee, Price D, Bosnic-Anticevich S, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013;107(1):37–46.
Virchow JC, Akdis CA, Darba J, et al. A review of the value of innovation in inhalers for COPD and asthma. J Mark Access Health Policy. 2015;3:28760.
Smith IJ, Bell J, Bowman N, Everard M, Stein S, Weers JG. Inhaler devices: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 2):S25–37.
Ninane V, Brusselle GG, Louis R, et al. Usage of inhalation devices in asthma and chronic obstructive pulmonary disease: a Delphi consensus statement. Expert Opin Drug Deliv. 2014;11(3):313–23.
Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593–604.
Weisfeld L, Shu Y, Shah TP. Bioequivalence of budesonide plus formoterol (BF) Spiromax(R) and BF Turbohaler(R) (with and without charcoal block) in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53(7):593–602.
Hsu C-C, Brian AS. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12:1–8.
Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. Int J Forecast. 1999;15:353–75.
Gordon TJ. The Delphi method. Washington, DC: American Council for the United Nations University; 1994.
Delbecq A, Van de Ven A, Gustafson D. Group techniques for program planning: a guide to nominal and Delphi processes. Glenview: Scott, Foresman & Company; 1975. p. 174.
Sandler N, Holländer J, Långström D, Santtila P, Saukkonen A, Torvinen S. Evaluation of inhaler technique mastery and handling errors with Spiromax®, Easyhaler®, and Turbuhaler® devices (FINHALER) [abstract]. In: Proceedings of the 17th Annual European congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 8–12 Nov 2014, Amsterdam, The Netherlands.
Bosnic-Anticevich S, Lim D, Steel J, et al. Investigating handling errors over time for inhaler devices: the healthcare professional perspective [abstract 1785]. Allergy. 2015;70(Suppl 101):645.
(GINA) GIfA. Global strategy for asthma management and prevention 2014 [07/2015]. http://www.ginasthma.org/. Accessed Nov 2015.
Ovchinikova L, Smith L, Bosnic-Anticevich S. Inhaler technique maintenance: gaining an understanding from the patient’s perspective. J Asthma. 2011;48(6):616–24.
Price D, Brusselle G, Roche N, Freeman D, Chisholm A. Real-world research and its importance in respiratory medicine. Breathe (Sheff). 2015;11(1):26–38.
Lavorini F. The challenge of delivering therapeutic aerosols to asthma patients. ISRN Allergy. 2013;2013:102418.
Scichilone N, Benfante A, Bocchino M, et al. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases? Pulm Pharmacol Ther. 2015;31:63–7.
Linstone H, Turoff M. The Delphi method: techniques and approaches. New Jersey Institute of Technology; 2002. http://is.njit.edu/pubs/delphibook/. Accessed Nov 2015.